Study of Let-7a and miRNA-124 in Cases of Non-Hodgkin's Lymphoma and Acute Leukemia

Not Applicable

• Conditions: Non Hodgkin Lymphoma and Acute Leukemia
• Interventions: Diagnostic Test: real time pcr

• Registration Number: NCT05477667
• Lead Sponsor: Sohag University

Brief Summary

MiRNAs are noncoding RNAs (ncRNAs) that drive post-transcriptional negative regulation of gene expression by promoting the degradation or translational blockade of their target mRNAs. MiRNAs are 21-24-nucleotide-long RNA molecules that are processed from longer RNA precursors (pri-miRNAs) , and either the 5' or the 3' strand of the mature miRNA duplex is loaded into the Argonaute (AGO) family of proteins to form a miRNA-induced silencing complex (miRISC) When bound to AGO proteins, mature miRNAs destabilize or inhibit the translation of partially complementary target mRNAsMiRNA-124 has been shown to be a tumor suppressor, and a decrease in its expression level is typical of tumors of various localization, but there is no evidence of the role of miRNA-124 in the development of NHL . There are a number of studies reflecting the involvement of miRNA-124 in hematopoiesis. Liu et al. showed that miRNA-124 regulates Tip110 that is involved in the differentiation of hematopoietic stem cellsThe let-7 family has been shown to influence the pathogenesis of a variety of hematological malignancies through the changing expression of a number of oncogenic pathways, particularly those related with MYC and that might affect hematopoietic carcinogenesis through the modulation of inflammatory pathways

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2022-07
• Study First Submitted: 2022-07-26
• Study First Submitted QC: 2022-07-26
• Last Update Submitted: 2022-07-26
• Study First Posted: 2022-07-28
• Last Update Posted: 2022-07-28
• Study Start: 2022-10-01
• Primary Completion: 2023-04-30
• Study Completion: 2023-04-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• approval to sign an informed written consent,
• patient with NHL and acute leukemia .

Read More

Exclusion Criteria

• Refusal to sign an informed written consent,
• patient on chemotherapy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
the cases (A)	real time pcr	NHL .
control group	real time pcr	the patients with non-malignant hematological diseases
the cases (B)	real time pcr	acute leukemia

Primary Outcome Measures

Name	Time	Method
MiRNA-124 level	6 months	Detection of expressin level of MiRNA-124 IN Non-Hodgkin's Lymphoma and acute leukemia
let-7a level	6 months	Detection of expressin level of let-7a IN Non-Hodgkin's Lymphoma and acute leukemia

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt